Analyst Downgrades – FibroGen (NASDAQ:FGEN) Stock Gets Downgraded By Goldman Sachs Group, Inc. (The) from Buy to Neutral

ME Staff
-
0

Analyst Ratings For FibroGen (NASDAQ:FGEN)

Today, FibroGen (NASDAQ:FGEN) stock was downgraded by Goldman Sachs Group, Inc. (The) from Buy to Neutral.

There are 1 hold rating, 7 buy ratings on the stock.

The current consensus rating on FibroGen (NASDAQ:FGEN) is Buy (Score: 2.88) with a consensus target price of $45.00 per share, a potential 28.76% upside.

Some recent analyst ratings include

  • 7/21/2017-Goldman Sachs Group, Inc. (The) was Downgraded by analysts at Goldman Sachs Group, Inc. (The) from a “Buy ” rating to a ” Neutral” rating.
  • 7/10/2017-Jefferies Group LLC initiated coverage with a Buy rating.
  • 6/26/2017-Citigroup Inc. Reiterated Rating of Buy.
  • 6/26/2017-William Blair Reiterated Rating of Outperform.
  • 6/22/2017-Stifel Nicolaus Reiterated Rating of Buy.
  • 1/18/2017-Royal Bank Of Canada Reiterated Rating of Buy.
  • 11/9/2016-Leerink Swann Reiterated Rating of Buy.

Recent Insider Trading Activity For FibroGen (NASDAQ:FGEN)
FibroGen (NASDAQ:FGEN) has insider ownership of 14.90% and institutional ownership of 43.83%.

  • On 7/17/2017 Kalevi Kurkijarvi, Director, sold 2,000 with an average share price of $33.45 per share and the total transaction amounting to $66,900.00. View SEC Filing
  • On 7/10/2017 K Peony Yu, Insider, sold 5,000 with an average share price of $32.98 per share and the total transaction amounting to $164,900.00. View SEC Filing
  • On 7/7/2017 Thomas B Neff, CEO, sold 38,636 with an average share price of $33.38 per share and the total transaction amounting to $1,289,669.68. View SEC Filing
  • On 7/6/2017 Pat Cotroneo, VP, sold 4,000 with an average share price of $34.00 per share and the total transaction amounting to $136,000.00. View SEC Filing
  • On 7/6/2017 Thomas B Neff, CEO, sold 18,900 with an average share price of $33.53 per share and the total transaction amounting to $633,717.00. View SEC Filing
  • On 6/22/2017 Pat Cotroneo, VP, sold 3,000 with an average share price of $32.00 per share and the total transaction amounting to $96,000.00. View SEC Filing
  • On 6/22/2017 Thomas B Neff, CEO, sold 38,636 with an average share price of $31.52 per share and the total transaction amounting to $1,217,806.72. View SEC Filing

Recent Trading Activity for FibroGen (NASDAQ:FGEN)
Shares of FibroGen closed the previous trading session at 34.95 down -0.30 -0.85% with 367,476 shares trading hands.